Article
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
The oncologist - 1 Nov 2018
García-Alfonso Pilar, Benavides Manuel, Falcó Esther, Muñoz Andrés, Gómez Auxiliadora, Sastre Javier, Rivera Fernando, Montagut Clara, Salgado Mercedes, López-Ladrón Amelia, López Rafael, Ruiz de Mena Inmaculada, Durán Gema, Aranda Enrique
Abstract excerpt
LESSONS LEARNED: RAS- or BRAF-mutated metastatic colorectal cancers (mCRCs) progressing after first-line treatment have a poor prognosis.European and U.S. guidelines include the multikinase inhibitor regorafenib as a standard option for second-line therapy and beyond, based on the results of the randomized phase III CORRECT trial demonstrating improvement in survival.Although stopped prematurely for failing to...
Topics
Join the communities discussing this publication.